Obesity in Adolescents with Psychiatric Disorders
- 139 Downloads
Purpose of Review
This narrative review synthesized recent research related to obesity in adolescents with psychiatric disorders, with a focus on epidemiology, mechanisms, and weight management approaches. The paper reviews literature on depressive and anxiety disorders, bipolar disorder, and schizophrenia spectrum and other psychotic disorders.
Depression has a bidirectional relationship with obesity. Bipolar disorder and schizophrenia spectrum disorders, and their treatments, increase the risk of developing obesity. Mechanisms underlying this weight gain include lifestyle and environmental factors and psychiatric medications, though emerging evidence has also suggested the role of genetic and neuroendocrine processes. Evidence about the most effective treatments for obesity in adolescents with psychiatric disorders remains limited.
Adolescents with psychiatric disorders are at high risk for obesity. Close monitoring for increases in weight and cardiometabolic risk factors with use of antipsychotic and mood-stabilizing medications is recommended. Clinical trials are needed that test the efficacy of weight management strategies for this population.
KeywordsAdolescence Obesity Psychiatric disorders Depression Bipolar disorder Schizophrenia
Ariana M. Chao was supported, in part, by the National Institute of Nursing Research of the National Institutes of Health under Award Number K23NR017209. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Ariana M. Chao reports grants and personal fees from Shire Pharmaceuticals, outside the submitted work.
Thomas A. Wadden reports grants and personal fees from Novo Nordisk, grants from Eisai Pharmaceuticals, and personal fees from Weight Watchers, outside the submitted work.
Robert I. Berkowitz reports a research grant and personal fees from Eisai Inc., outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2017.Google Scholar
- 8.Centers for Disease Control Prevention. Clinical Growth Charts. 2017. https://www.cdc.gov/growthcharts/clinical_charts.htm. Accessed July 26 2018.
- 16.Marmorstein NR, Iacono WG, Legrand L. Obesity and depression in adolescence and beyond: reciprocal risks. Int J Obes. 2014;38(7):906–11.Google Scholar
- 18.•• Mannan M, Mamun A, Doi S, Clavarino A. Prospective associations between depression and obesity for adolescent males and females—a systematic review and meta-analysis of longitudinal studies. PLoS One. 2016;11(6):e0157240 This meta-analysis includes 13 longitudinal studies assessing the bidirectional relationship between obesity and depression.PubMedPubMedCentralGoogle Scholar
- 23.• Bioque M, García-Portilla MP, García-Rizo C, Cabrera B, Lobo A, González-Pinto A, et al. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophr Res. 2018;193:188–96 This study examined weight gain and metabolic changes in a cohort of patients with FEP over 2 years.PubMedGoogle Scholar
- 26.• Goldstein BI, Blanco C, He J-P, Merikangas K. Correlates of overweight and obesity among adolescents with bipolar disorder in the National Comorbidity Survey–Adolescent supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2016;55(12):1020–6 This study examines the relationship of overweight/obesity in a nationally representaive sample of adolescents with bipolar disorder, major depressive disorder, and control using face-to-face surveys.PubMedGoogle Scholar
- 44.•• Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M et al. First-and second-generation antipsychotics in children and young adults: systematic review update. Rockville (MD): Agency for Healthcare Research and Quality; 2017 Contract No.: 17-EHC001-EF. This provides a comprehensive review of first-and second generation antipsychotics in children and young adults.Google Scholar
- 46.Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T, Canadian Alliance for Monitoring Effectiveness, et al. Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health. 2011;16(9):575–80.PubMedPubMedCentralGoogle Scholar
- 48.•• Pillay J, Boylan K, Newton A, Hartling L, Vandermeer B, Nuspl M et al. Harms of antipsychotics in children and young adults: a systematic review update. Can J Psychiatry. 2018. This included 135 studies on the harms of first- and second-generation treatment of psychiatric conditions in youth, and includes a review of these medications on weight gain.Google Scholar
- 52.• Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659–74 This network meta-analysis synthesizes data from 28 randomized controlled trials comparing symptoms of schizophrenia in youth including weight gain.PubMedGoogle Scholar
- 58.Jerrell JM, McIntyre RS. Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study. Prim Care Companion J Clin Psychiatry. 2010;12(4):e1–8.Google Scholar
- 73.Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:92–9.Google Scholar
- 75.•• The National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155. Accessed July 26 2018. These are clinical guidelines about the management of psychosis and schizophrenia in children and young people.
- 76.Sussex Partnership of the NHS. Guidance on the Use of Antipsychotics. 2015. http://www.sussexpartnership.nhs.uk/sites/default/files/documents/antipsychotic_guidelines_version_3.2_-_oct_15_-_with_new_hdat_form_added_-_dec_16_0.pdf. Accessed July 26 2018.
- 78.American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.Google Scholar
- 84.• Teasdale SB, Ward PB, Rosenbaum S, Watkins A, Curtis J, Kalucy M, et al. A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. Br J Nutr. 2016;115(11):1987–93 This study evaluated the feasibility and effectiveness of a 12-week nutrition intervention in participants ages 15–25 years with FEP.PubMedGoogle Scholar
- 85.Ignaszewski MJ, Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: a systematic review. J Child Adolesc Psychopharmacol. 2018;28:668–75.Google Scholar
- 87.Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117166.PubMedPubMedCentralGoogle Scholar
- 88.Goldstein BI, Sassi R, Diler RS. Pharmacologic treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatric Clin. 2012;21(4):911–39.Google Scholar
- 94.• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–9 This is a small, 16-week placebo-controlled trial demonstating the safety and efficacy of metformin in youth taking second-generation antipsychotics.PubMedGoogle Scholar
- 95.ClinicalTrials.gov. Metformin for overweight & obese children and adolescents with BDS treated with SGAs (MOBILITY). 2017. https://clinicaltrials.gov/ct2/show/NCT02515773. Accessed July 25 2018.
- 99.Mackey ER, Wang J, Harrington C, Nadler EP. Psychiatric diagnoses and weight loss among adolescents receiving sleeve gastrectomy. Pediatrics. 2018:e20173432.Google Scholar
- 101.Hilt R, Marx L, Pierce K, Sarvet B, Becker E, Kendrick J et al. A guide to building collaborative mental health care partnerships in pediatric primary care. 2010.Google Scholar